But emerging research suggests GLP-1 medications may be able to help reduce fat accumulation in the liver and support the management of MASLD, Dr
Long-acting GLP-1 receptor agonists (e.g., albiglutide [no longer commercially available in the US], dulaglutide, exenatide extended-release, liraglutide, semaglutide) induce marked reductions in fasting plasma glucose (by stimulating insulin secretion) and modest reductions in postprandial glucose, while short-acting GLP-1 receptor agonists (e.g., exenatide, lixisenatide), have less of an effect on fasting plasma glucose concentrations and more of an effect on reducing postprandial glucose concentrations (by slowing gastric emptying and inhibiting glucagon secretion)
Include comprehensive documentation: lab results, weight history, prior treatment attempts, and a letter of medical necessity
The solution, for the most part, is to strengthen our meal pattern, fueling our body more regularly and consistently, but without grazing